Julia Hegge

机构：Arrowhead Pharmaceuticals (United States)

发表论文 79 篇 · 总被引 1772 次 · h-index 22

代表论文

• Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD (2024 · New England Journal of Medicine · 被引 65)
• Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease (2020 · JCI Insight · 被引 59)
• A clinical-stage RNAi therapeutic candidate for IPF mediates durable MMP7 silencing in nonhuman primates and human lung tissue (2023 · 被引 3)
• Lung-targeted RNAi Molecules Silence Human TSLP Expression in PCLS Cultures and Humanized Mice and Suppress Pulmonary Allergic Inflammation (2024 · 被引 1)
• A Lung-Targeted RNAi Therapeutics Delivery Platform Compatible With Subcutaneous (s.c.) Administration Mediates Pulmonary RAGE Silencing In Rodents And Nonhuman Primates (2023 · 被引 1)
• Silencing TSLP expression with a lung-targeted RNAi molecule suppresses pulmonary allergic inflammation (2023 · 被引 1)